The introduction of prostaglandin analogues and mifepristone has changed the management of second trimester abortion in the last 2 decades. Gemeprost and misoprostol are the two most extensively studied prostaglandin analogues that are used in this period. The combination of either gemeprost or misoprostol with mifepristone is most effective. With these regimens, over 90% of women abort within 24 hours and the mean induction to abortion interval is about 6 hours. Mifepristone is expensive and is not available in many countries. Therefore, prostaglandin analogue-only regimens might be the only option. These regimens are still effective with an abortion rate of >90% in 48 hours. However, the induction to abortion interval (15 hours) is much longer. Intra-cervical tents can be used to shorten the induction to abortion intervals.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/beog.2001.0273 | DOI Listing |
Obstet Gynecol
January 2025
Department of Obstetrics and Gynecology and the Division of Maternal Fetal Medicine, University of Kansas School of Medicine, Kansas City, Kansas.
Obesity is a chronic condition that causes significant morbidity and mortality in people in the United States and around the world. Traditional means of weight loss include diet, exercise, behavioral modifications, and surgery. New weight loss medications, glucagon-like peptide-1 receptor agonists, are revolutionizing the management of weight loss but have implications for fertility and pregnancy.
View Article and Find Full Text PDFCochrane Database Syst Rev
January 2025
Institute of Education in Healthcare and Medical Sciences, University of Aberdeen, Aberdeen, UK.
Background: Gonadotropin-releasing hormone agonists (GnRHa) are commonly used in assisted reproduction technology (ART) cycles to prevent a luteinising hormone (LH) surge during controlled ovarian hyperstimulation (COH) prior to planned oocyte retrieval, thus optimising the chances of live birth. We compared the benefits and risks of the different GnRHa protocols used.
Objectives: To evaluate the effectiveness and safety of different GnRHa protocols used as adjuncts to COH in women undergoing ART.
J Obstet Gynaecol India
December 2024
DNB Resident, Department of Obstetrics and Gynaecology, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan India.
Introduction: MTP has been legalized in India through the Medical Termination of Pregnancy Act, of 1971, which allows pregnancy termination up to 20 weeks. The present study included second-trimester pregnancy terminations and the main aim of the study is to compare the efficacy and safety of tablet mifepristone 24 h before vaginal tablet misoprostol in group-I with vaginal tablet misoprostol alone in group-II as a method of second-trimester pregnancy termination.
Methodology: It was a prospective randomized comparative study conducted at the Department of Obstetrics and Gynaecology, R.
Drug Des Devel Ther
January 2025
Department of Anesthesiology, Ningbo No. 2 hospital, Ningbo, 315010, People's Republic of China.
Objective: This study aims to compare the recovery profiles of remimazolam combined with flumazenil against those of propofol in patients undergoing painless surgical abortion, focusing on psychomotor function and emergence. Rapid recovery and restoration of psychomotor function are critical for enhancing patient safety and satisfaction in outpatient procedures like surgical abortion.
Methods: A total of 110 patients scheduled for surgical abortion were randomly assigned to either the remimazolam group (Group R) or the propofol group (Group P) in a 1:1 ratio.
Ochsner J
January 2024
Department of Allergy and Immunology, Ochsner Clinic Foundation, New Orleans, LA.
Allergists perform a range of procedures with inherent risks of anaphylaxis. This study developed risk assessments for various procedures performed at our specialized referral center based on the frequency of epinephrine use during these procedures. During a 5.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!